¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

Edge-to-Edge Repair Reduces Hospitalization and Mortality Rates in Secondary Mitral Valve Regurgitation?

Severe secondary mitral valve regurgitation is associated to hospitalization and mortality.  The COAPT study has shown the superiority of guideline directed medical therapy at maximal tolerated doses according to guidelines (GDMT) plus edge-to-edge transcatheter repair (TEER) versus GMDT alone. However, at present there is no information on the impact of hospitalizations and their relationship to<a href="https://solaci.org/en/2022/11/22/edge-to-edge-repair-reduces-hospitalization-and-mortality-rates-in-secondary-mitral-valve-regurgitation/" title="Read more" >...</a>

Opening Ceremony SOLACI-SOCIME 2022

✔️ Opening Ceremony SOLACI-SOCIME 2022 ✔️ SOLACI-SOCIME 2022 Scientific Session 👨‍🏫 Content: 00:09 – Welcoming words – Dr. Guering Eid-Lidt (MEX) 01:41 – Fully understanding our TAVR implantation views and techniques – Dr. Ole de Backer (DNK) 21:51 – Transcatheter interventional heart failure therapies – Dr. Juan Granada (USA) 43:17 – The revolution in the<a href="https://solaci.org/en/2022/09/15/opening-ceremony-solaci-socime-2022-2/" title="Read more" >...</a>

Apixaban and Valve Thrombosis after TAVR

TAVR has been associated with early valve thrombosis, characterized by thrombus formation in the prosthetic valve with or without valve dysfunction. This dysfunction is related to leaflet thickening and reduced motion, reduced effective orifice area, or increased transvalvular gradient. A multidetector CT scan allows the dynamic assessment of valves and ruling out fibrosis vs. thrombosis. <a href="https://solaci.org/en/2022/09/14/apixaban-and-valve-thrombosis-after-tavr/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

TAVR in Bicuspid Patients: Are Outcomes the Same in Men and Women?

Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in this scenario has been assessed only by small fairly studies. However, the information available is quite promising.   TAVR in women generally presents more complications than in men, but severe bicuspid aortic valve stenosis receiving TAVR has not been<a href="https://solaci.org/en/2022/08/26/tavr-in-bicuspid-patients-are-outcomes-the-same-in-men-and-women/" title="Read more" >...</a>

Post-dilatación de válvulas autoexpandibles

Balloon expandable vs Self-Expanding Valves: The Best Option for ViV-TAVR in Small Annuli

TAVR has consolidated as an increasingly valid alternative to treat failed surgical aortic valve bioprostheses.   One of the major challenges it presents is patients with small annuli treated with a surgical bioprosthesis.  There is little data available about this scenario. A few observational studies have shown what appears to be a hemodynamic advantage of<a href="https://solaci.org/en/2022/08/23/balloon-expandable-vs-self-expanding-valves-the-best-option-for-viv-tavr-in-small-annuli/" title="Read more" >...</a>

Surgical Bioprosthesis Deterioration: Is the Valve-in-Valve Technique a Good Option?

The use of surgical bioprostheses has significantly increased, and while they last 15 years or more, in cases where they fail (usually due to stenosis), the decision-making process is challenging. Transcatheter aortic valve replacement (TAVR) is a good alternative for this situation, although information on the subject matter is still scarce. Currently, the only available<a href="https://solaci.org/en/2022/08/18/surgical-bioprosthesis-deterioration-is-the-valve-in-valve-technique-a-good-option/" title="Read more" >...</a>

Non-Cardiac Surgery After TAVR Is Safe

There are increasingly more patients who have undergone transcatheter aortic valve replacement (TAVR) and require a non-cardiac intervention, or patients with other diseases who need surgery and are diagnosed with aortic stenosis.  In addition, on many occasions, surgery must be performed as soon as possible (as in cases of cancer) or is an emergency procedure.<a href="https://solaci.org/en/2022/08/11/non-cardiac-surgery-after-tavr-is-safe/" title="Read more" >...</a>

New-Generation ACURATE Neo2

Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce<a href="https://solaci.org/en/2022/06/03/new-generation-acurate-neo2/" title="Read more" >...</a>

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Should Revascularization Be Performed Before TAVR in Patients with Stable Coronary Disease?

Currently, the American and European guidelines recommend coronary angioplasty in patients with severe aortic stenosis with lesions >70% (Class IIa) who will undergo transcatheter aortic valve replacement (TAVR). However, the benefit of performing a revascularization in these patients is still uncertain. This prospective multicenter study included 2025 patients divided into two groups: complete revascularization (N = 1310)<a href="https://solaci.org/en/2022/05/24/europcr-2022-should-revascularization-be-performed-before-tavr-in-patients-with-stable-coronary-disease/" title="Read more" >...</a>

EuroPCR 2022 | GLOBAL SYMPLICITY Registry

The GLOBAL SYMPLICITY Registry is the largest study, with the longest followup, of real-world patients (real world data) presenting high blood pressure, treated with renal denervation.  Time in Target Range (TTR), estimates the time a patient needs to control their blood pressure, and is an independent predictor of cardiovascular events.  The aim of this registry,<a href="https://solaci.org/en/2022/05/23/europcr-2022-global-symplicity-registry/" title="Read more" >...</a>